Trends in the use of immunotherapy to treat soft tissue sarcoma

Trends in the use of immunotherapy to treat soft tissue sarcoma

The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS. This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011–2021. Patients were categorized by IO receipt status. Groupwise t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of surgery 2024-10, Vol.236, p.115794, Article 115794
Hauptverfasser: Iwai, Yoshiko, Baldwin, Xavier L., Feeney, Timothy, Agala, Chris B., Yanagihara, Ted K., Stein, Jacob N., Kim, Hong Jin, Spanheimer, Philip M.
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Cancer therapies
Chi-square test
Contraindications
Ethnicity
Immune checkpoint inhibitor
Immune system
Immunotherapy
Metastases
Metastasis
Patients
Regression analysis
Research facilities
Response rates
Sarcoma
Soft tissue mass
Soft tissue sarcoma
Soft tissues
Trends
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS. This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011–2021. Patients were categorized by IO receipt status. Groupwise testing and proportional trend tests were performed with Chi-squared tests. Multivariate logistic regression was performed to assess factors associated with IO receipt. Of the 103,092 patients with STS, 1935 (1.9 ​%) received or were recommended IO therapy. IO use increased 10-fold (0.24 ​%–2.5 ​% from 2011 to 2021; p ​
ISSN:0002-9610
1879-1883
1879-1883
DOI:10.1016/j.amjsurg.2024.115794